Verition Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Verition Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	446,947 +34,200	+8%	+$114K	0.01%	1202
2026 Q1	$1.27M	Hold	412,747	–	–	0.01%	1215
2025 Q4	$1.69M	Buy	412,747 +358,169	+656%	+$1.77M	0.01%	1760
2025 Q3	$266K	Sell	54,578 -168,638	-76%	-$886K	﹤0.01%	3351
2025 Q2	$1.13M	Buy	223,216 +113,703	+104%	+$559K	0.01%	2381
2025 Q1	$579K	Buy	+109,513	New	+$798K	﹤0.01%	2492
2023 Q2	–	Sell	-33,400	Closed	-$223K	–	2492
2023 Q1	$223K	Buy	+33,400	New	+$265K	﹤0.01%	1705

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Verition Fund Management's RXRX Position: Q2 2026 in Review

Verition Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 8.3% in Q2 2026, buying an estimated $114K and bringing the position to 446,947 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #1202.

Verition Fund Management first reported a position in RXRX in Q1 2023 and has held it in 7 quarters since. The position peaked at $1.69M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Verition Fund Management held 446,947 shares of Recursion Pharmaceuticals worth $1.64M as of Q2 2026.
Verition Fund Management bought 34,200 Recursion Pharmaceuticals shares in Q2 2026, an estimated $114K.
Recursion Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1202 holding.
Verition Fund Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Verition Fund Management's Recursion Pharmaceuticals position peaked at $1.69M in Q4 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.